术后口服补液量对直接经皮冠状动脉介入治疗后对比剂诱导急性肾损伤风险的影响:随机对照试验研究方案
本研究为ATTEMPT研究的二次分析,纳入接受直接PCI的STEMI患者,随机接受围术期积极(左心室舒张末压引导)或常规(≤500 mL)静脉补液(0.9% NaCl)。主要终点为对比剂诱导急性肾损伤(CI-AKI),定义为术后48-72小时内血清肌酐较基线升高>25%或0.5 mg/dL。记录术后24小时内自由口服补液量并计算口服补液量/体重比值,采用多因素分析评估术后口服补液四分位数与CI-AKI的关联。
要点
- 研究评估术后口服补液量对直接PCI后CI-AKI风险的影响
- CI-AKI定义为术后48-72小时内血清肌酐较基线升高>25%或0.5 mg/dL
- 术后口服补液量按四分位数分组,采用多因素分析控制混杂因素
核心结论
- 本研究旨在确定术后口服补液对直接PCI后CI-AKI的影响,该策略可能是极高危STEMI患者预防CI-AKI的潜在方法。
研究设计与样本
- 本研究为ATTEMPT研究的二次分析,纳入接受直接PCI的ST段抬高型心肌梗死(STEMI)患者。
- 符合条件的患者随机接受围术期积极(左心室舒张末压引导)或常规(≤500 mL)静脉补液,使用等渗溶液(0.9% NaCl)。
主要发现
- 所有患者自由不限量饮水,记录直至直接PCI后24小时的液体量,并计算口服补液量/体重比值。
- 采用多因素分析评估术后口服补液(四分位数)与CI-AKI的关联,控制包括静脉补液策略在内的混杂因素。
关键数值与推荐
- 主要终点CI-AKI定义为术后48-72小时内血清肌酐较基线升高>25%或0.5 mg/dL。
- 常规静脉补液量为≤500 mL的等渗溶液(0.9% NaCl)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Contrast-induced acute kidney injury (CI-AKI) contributes toward unfavorable clinical outcomes. Oral hydration with water is inexpensive and it may be effective in the prevention of CI-AKI, but its efficacy among patients undergoing primary percutaneous coronary intervention (PCI) remains unknown. METHODS/DESIGN: Our study is a secondary analysis on the database from the ATTEMPT study. We enrolled ST-elevation myocardial infarction (STEMI) patients undergoing primary PCI. Eligible patients received peri-procedural aggressive (left ventricular end-diastolic pressure-guided) or routine (≤ 500 mL) intravenous hydration with an isotonic solution (0.9% NaCl) with randomization. The primary endpoint was CI-AKI, defined as a > 25% or 0.5 mg/dL increase in serum creatinine from baseline during the first 48-72 h post-procedurally. All patients drank unrestricted amounts of fluids freely, the volume of which was recorded until 24 h following primary PCI. Oral hydration volume/weight (OHV/W) ratios were calculated. The association between post-procedural oral hydration (quartiles) and CI-AKI was assessed using multivariable analysis controlling for confounders, including intravenous hydration strategies. DISCUSSION: Our study determined the effects of post-procedural oral hydration on CI-AKI following primary PCI, which is a potential strategy for CI-AKI prevention among patients with STEMI at very high risk. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02067195 . Registered on 21 February 2014.
引用
- Song F, Sun G, Liu J, et al. Efficacy of post-procedural oral hydration volume on risk of contrast-induced acute kidney injury following primary percutaneous coronary intervention: study protocol for a randomized controlled trial. Trials. 2019. PMID: 31133052. doi:10.1186/s13063-019-3413-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。